Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HisTAC (polyHis-targeting chimera) is a ligand-independent targeted protein degradation (TPD) platform designed to degrade proteins of interest (POIs) that have been engineered with a polyhistidine tag. The system utilizes a nickel-nitrilotriacetic acid (Ni2+-NTA) moiety to bind the polyhistidine tag on the target protein and a separate ligand to recruit an E3 ubiquitin ligase, such as Cereblon (CRBN) or Von Hippel-Lindau (VHL). This proximity-induced approach facilitates the ubiquitination and subsequent proteasomal degradation of the tagged protein. HisTAC is particularly useful for studying traditionally undruggable targets or proteins lacking high-affinity small-molecule ligands, as it bypasses the need for a specific POI-binding ligand. It has demonstrated efficacy in degrading His-tagged versions of BRD4 and the RNA-binding protein PSPC1 in cellular models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HisTAC.